Report Overview - The report provides an overview of the A-share market, ETFs, and other financial instruments on January 23, 2026 [2][6]. Market Overview - The Shanghai Composite Index rose 0.33% to 4136.16 points, the Shenzhen Component Index rose 0.79% to 14439.66 points, and the ChiNext Index rose 0.63% to 3349.50 points [2][6]. - The total trading volume of A-shares was 31184 billion yuan [2][6]. - The top-performing sectors were power equipment (3.50%), non-ferrous metals (2.73%), and national defense and military industry (2.65%), while the worst-performing sectors were communication (-1.52%), banking (-0.90%), and coal (-0.76%) [2][6]. Stock ETF - The top-traded stock ETFs were Huatai-PineBridge CSI 300 ETF (-0.49%, discount rate -0.56%), E Fund CSI 300 ETF (-0.46%, discount rate -0.59%), and ChinaAMC CSI 300 ETF (-0.49%, discount rate -0.59%) [3][7]. Bond ETF - The top-traded bond ETFs were Haifutong CSI Short-term Financing Bond ETF (0.02%, discount rate 0.00%), ChinaAMC Shanghai Stock Exchange Benchmark Market-making Treasury Bond ETF (0.09%, discount rate 0.13%), and Bosera CSI Convertible and Exchangeable Bond ETF (1.28%, discount rate 1.26%) [4][9]. Gold ETF - Gold AU9999 rose 2.46%, and Shanghai Gold rose 2.55%. The top-traded gold ETFs were HuaAn Gold ETF (2.67%, discount rate 2.57%), E Fund Gold ETF (2.73%, discount rate 2.59%), and Bosera Gold ETF (2.67%, discount rate 2.59%) [12]. Commodity Futures ETF - Dacheng Non-ferrous Metals Futures ETF rose 1.61% with a discount rate of 1.56%, China Construction Bank Yisheng Zhengzhou Commodity Exchange Energy and Chemical Futures ETF rose 2.54% with a discount rate of 3.68%, and ChinaAMC Feed Soybean Meal Futures ETF fell 0.30% with a discount rate of 3.57% [13]. Cross-border ETF - The previous trading day, the Dow Jones Industrial Average rose 0.63%, the Nasdaq Composite rose 0.91%, the S&P 500 rose 0.55%, and the German DAX rose 1.20%. On January 23, the Hang Seng Index rose 0.45%, and the Hang Seng China Enterprises Index rose 0.51%. The top-traded cross-border ETFs were E Fund CSI Hong Kong Securities Investment Theme ETF (-0.58%, discount rate -1.29%), GF CSI Hong Kong Innovative Drug ETF (1.30%, discount rate 0.79%), and Huatai-PineBridge Hang Seng Technology ETF (0.67%, discount rate -0.21%) [16]. Money Market ETF - The top-traded money market ETFs were Silver HuaRui Daily Interest ETF, Huabao Tianyi ETF, and China Construction Bank Money Market ETF [18].

Group 1 - The core viewpoint of the news highlights the significant growth and potential of China's innovative pharmaceuticals, particularly in the context of international expansion and investment confidence [1] - The year 2025 is marked as a pivotal year for China's innovative pharmaceuticals, with total outbound licensing transaction amounts reaching $135.655 billion and a record 157 transactions [1] - The continuous successful BD transactions validate the global competitiveness of Chinese innovative drugs, supporting long-term investment confidence [1] Group 2 - The small nucleic acid drug sector is making notable progress, with leading companies accelerating their development in new target discovery and treatment convenience, attracting increased attention [1] - The GLP-1 sector is expected to have long-term market potential following the establishment of a new pricing system [1] - Domestic companies are actively pursuing relevant targets in the oral autoimmune drug space, indicating significant value [1] Group 3 - The brain-computer interface technology is at a critical juncture for industrialization, with substantial advancements in policy support, device approval, insurance coverage, and clinical applications [1] - Developments in radiation therapy equipment technology are creating new market opportunities worth billions [1] Group 4 - The ETF Guotai (589720) tracks the innovative drug index (950161), which includes listed companies engaged in innovative drug research and development, covering various fields such as biopharmaceuticals, chemical drugs, and traditional Chinese medicine [2] - The index reflects the overall performance of listed companies in China's pharmaceutical innovation sector [2]

Core Insights - The article discusses the recent performance of the ChiNext AI ETF Guotai (159388), which has seen a decline of over 1.2% on January 23, while experiencing a net inflow of over 100 million yuan in the past 10 days, highlighting the focus on technological independence and AI application progress [1] Group 1: AI and Cloud Developments - The report mentions that Qianwen App has integrated with Alibaba's ecosystem, launching AI Agent capabilities and achieving AI shopping functionality [1] - OpenAI and Google are actively investing in the AI + healthcare sector [1] - A BCG survey indicates that over 90% of enterprises plan to maintain long-term investments in AI, with some intending to double their AI investments by 2026 [1] Group 2: Market Outlook and Index Information - Alibaba Cloud aims to capture 80% of the incremental AI cloud market in China by 2026 [1] - The ChiNext AI ETF tracks the ChiNext AI Index (970070), which has a daily price fluctuation limit of 20% and selects listed companies involved in AI technology and applications from the ChiNext market [1] - The index focuses on high-tech growth companies, emphasizing innovation capability and future development potential [1]

Group 1 - The core viewpoint of the article highlights the impact of new medical pricing policies on the surgical robotics market, which is expected to enhance the commercialization of surgical robots by establishing clearer pricing structures and reimbursement models [1] - The National Healthcare Security Administration has released a guideline focusing on pricing for surgical and treatment auxiliary medical services, which includes three pricing projects for robotic-assisted surgeries: navigation, participation, and precision execution [1] - The new pricing model links reimbursement rates to the complexity and effectiveness of the robotic surgeries, allowing for higher fees for more advanced and capable surgical robots [1] Group 2 - The guideline also introduces a standardized pricing project for "remote surgical assistance," which is expected to facilitate the large-scale application of remote surgeries and promote the expansion of quality medical resources across regions [1] - Additionally, the policy incorporates the storage and upload of medical data and device operation records into the pricing structure, aiming to provide a data foundation for technological iteration and application expansion [1] - The regulation clarifies the pricing boundaries for reusable and disposable consumables, promoting more transparent and standardized clinical charging practices [1]

Group 1 - The core viewpoint of the articles highlights the positive signals released by JPM meetings, reinforcing the industrial positioning of AI in healthcare [1] - AI in pharmaceuticals is enhancing the entire drug development process, improving efficiency and success rates in new drug discovery, preclinical screening, clinical development, and production, indicating a high growth trajectory in the future [1] - Since the beginning of 2026, multinational pharmaceutical companies have engaged in over 9 AI-related collaborations, totaling more than $6 billion [1] Group 2 - Chinese innovative pharmaceutical companies are demonstrating competitive strength, with a surge in outbound business development for dual antibodies, ADCs, and GLP-1RA new drugs expected by 2025 [1] - The investment direction in AI healthcare includes areas such as AI health management, AI medical information technology, AI medical imaging, AI surgical robots, AI gene sequencing, and AI pharmaceuticals [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on listed companies dedicated to innovative drug research and development in the biopharmaceutical and chemical pharmaceutical sectors [1]

Group 1 - The core viewpoint indicates that the market is expected to maintain an upward trend, supported by over 12 billion yuan of net inflow into the CSI A500 ETF (159338) over the past 60 days [1] - Recent regulatory policies are anticipated to guide market sentiment back to rationality, enhancing the inherent stability of the market [1] - The investment focus is expected to shift from macro liquidity drivers to micro performance verification as the annual earnings forecasts of listed companies are set to be disclosed intensively in late January [1] Group 2 - The CSI A500 index emphasizes industry balance and leading companies in specific sectors, offering a more diversified style and higher growth exposure, which provides a better Beta base during the industrial structure upgrade cycle [1] - As of the end of 2025, the CSI A500 index has increased by 464.28% since its base date, outperforming the CSI 300 index, which has risen by 361.15%, resulting in an excess return of 103.13 percentage points [1] - The number of accounts for the Guotai CSI A500 ETF is the highest among similar products, being more than three times that of the second-ranked product, indicating a growing interest among investors [1]

Group 1 - TSMC is expected to achieve record growth in 2025 driven by AI and advanced process technologies, with a significant increase in capital expenditure to $52-56 billion in 2026, exceeding market expectations [1] - The increase in capital expenditure aims to accelerate the construction of advanced process capacity to meet the ongoing global demand for AI computing power [1] Group 2 - The Cathay Innovation AI ETF (589110) tracks the Innovation AI Index (950180), which has a daily price fluctuation limit of 20% [1] - The index selects 30 listed companies from the Sci-Tech Innovation Board that cover AI foundational resources, core technology R&D, and industry application, reflecting the overall performance of enterprises in the AI sector [1]

（文章来源：每日经济新闻） 创业板人工智能ETF国泰（159388）跟踪的是创业板人工智能指数（970070），单日涨跌幅限制达 20%，该指数从创业板市场中选取涉及人工智能技术及相关应用领域的上市公司证券作为指数样本，涵 盖机器学习、智能硬件、大数据处理等行业，以反映创业板中人工智能相关上市公司证券的整体表现， 具有较高的成长性和创新性特征。 有券商指出，2026年行业配置视角要更加"以我为主"，通过科技自立自强巩固国家安全。从AI产业趋势 角度，看好国产算力及制造产业链，关注AI电力建设、AI眼镜新品、人形机器人和ToB端AI应用。同 时，需重视"十五五"规划相关的具身智能、6G等领域。分析师认为，一方面需突破产业围堵和技术封 锁，通过技术攻关、科技创新在AI革命中掌握主动权，提升产业链安全水平、实现核心环节自主可 控。 ...

2024年9月24日以来，资本市场进入回暖上涨阶段，恒生生物科技指数累计涨幅达78.6%，跑赢港股通 创新药指数，展现出高弹性与高夏普比率的特征。 | | 恒生生物科技 | 恒生港股通创新药 | 港股通创新药 | 恒生医疗保健 | 港股通医疗主题 | | --- | --- | --- | --- | --- | --- | | 年化收益率(%) | 59. 42 | 57.50 | 59.07 | 51. 55 | 53. 41 | | 年化波动率(%) | 41.03 | 42.66 | 43. 50 | 39. 35 | 41.58 | | 最大回撤(%) | -27.55 | -27.35 | -27.08 | -28.51 | -30. 54 | | 夏普比率 | 1.45 | 1. 35 | 1.36 | 1.31 | 1.28 | | 累计收益(%) | 78. 64 | 75.97 | 78. 14 | 67.74 | 70. 29 | | 2025年以来收益(%) | 67. 50 | 66. 61 | 69.44 | 59.83 | 51. 12 | 数据来源：Wind，2025年以来数据 ...

创业板新能源ETF国泰（159387）跟踪的是创新能源指数（399266），单日涨跌幅限制达20%，该指数 从沪深市场中聚焦于新能源领域的技术创新企业，成分股涵盖清洁能源、新能源汽车、储能技术等行 业。指数侧重于筛选具有高成长性与科技创新能力的上市公司证券，以反映新能源行业的发展趋势和技 术进步的整体表现。 （文章来源：每日经济新闻） 1月21日，创业板新能源ETF国泰（159387）收涨超1%，近5日资金净流入超1.4亿元，德国电动车补贴 利好锂电产业链。 华福证券指出，德国政府宣布拨款30亿欧元用于新购入电动汽车的家庭提供最高6000欧元的补贴，旨在 扶持电动车产业发展，补贴倾向纯电汽车和中低收入人群。预计该政策将带动电动车新增需求在0至80 万辆之间，对应电池新增需求0至48GWh，看好锂电需求增长带来的业绩增量。 ...